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Abstract
Immunity acquired from infection or vaccination protects humans from symptomatic hepatitis E. However, whether the risk of hepatitis E
virus (HEV) infection is reduced by the immunity remains unknown. To understand this issue, a cohort with 12 409 participants randomized
to receive the hepatitis E vaccine Hecolin or placebo were serologically followed up for 2 years after vaccination. About half (47%) of
participants were initially seropositive. A total of 139 infection episodes, evidenced by four-fold or greater rise of anti-HEV level or positive
seroconversion, occurred in participants who received three doses of treatment. Risk of infection was highest among the baseline
seronegative placebo group participants (2.04%). Pre-existing immunity and vaccine-induced immunity lower the risk signiﬁcantly, to 0.52%
and 0.30%, respectively. In conclusion, both vaccine-induced and naturally acquired immunity can effectively protect against HEV infection.
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Introduction
Hepatitis E virus (HEV) is a major cause of acute hepatitis
worldwide [1,2], occasionally also associated with chronic liver
damage among organ transplant recipients, and in HIV-infected
and other immunocompromised individuals [3,4]. Hepatitis E is
well-recognized as a major disease burden in many developing
countries of Asia, Africa and Latin America [5–7], while locally
acquired cases of acute hepatitis E are being increasingly
recognized in developed countries [8–10].
Although the prevention of symptomatic infection is the
primary goal of immunity, the effectiveness of prevention of
asymptomatic HEV infection is critical in several high-risk
populations [11]. One is pregnant women, whose mortality
rates can be up to 30% and with bad obstetric and fetal
outcomes [12–14]. The other group is persons with underlying
chronic liver disease, whose mortality is signiﬁcantly increased
by HEV superinfection [15–17]. The third group is persons
who are immunosuppressed such as those receiving chemo-
therapy or transplant recipients or HIV carriers, because HEV
infection in these patients will lead to chronic liver damage
[3,4]. Prevention of HEV infection is of particular public-health
importance in the control of outbreaks by limiting virus
transmission, especially in hyperendemic areas where an
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infected person is almost the sole reservoir of HEV. Two
vaccine candidates are safe and efﬁcacious against symptomatic
HEV infection [18,19]. Epidemiological evidence shows that
individuals with naturally acquired anti-HEV antibodies are
protected from severe hepatitis E infection. However,
whether the risk of HEV infection is reduced by their immunity
remains unknown. In this report, we describe the results of an
extension of the phase 3 efﬁcacy in which serum samples were
obtained from a subpopulation of the larger cohort in the
efﬁcacy study before and at different times after vaccination to
establish the baseline immunity of the cohort and determine
the protection against HEV infection by immunity obtained
from natural infection and vaccination.
Methods
Subjects
This study is an extension of a randomized double-blind
placebo-controlled phase 3 study undertaken among 112 604
adult volunteers from 11 rural townships in eastern China, to
determine the efﬁcacy of the hepatitis E vaccine HEV239, with
the brand name Hecolin, against hepatitis E [19]. All 14 094
participants from two of the 11 townships were designated as
the immunogenicity subset, who gave additional consent to
donate serum samples in months 0, 7, 19 and 31 of the study,
which were before and 1, 13 or 25 months after the full
vaccination course.
Intervention
As previously described [19], the enrolled healthy adults aged
16–65 years, regardless of their anti-HEV status, were ran-
domly assigned to the HEV vaccine Hecolin or the placebo
group and were given three doses of the respective vaccine in
months 0, 1 and 6. The Hecolin was produced by Xiamen
Innovax (Xiamen, China). A commercial hepatitis B vaccine
(Beijing Tiantan, China) was given as placebo.
Laboratory measurements
Infection with HEV occurring in the 24 months after vaccina-
tion was monitored by comparing the antibody levels in paired
serum samples obtained in months 7 and 19 and in months 19
and 31, respectively. Immunogenicity of the HEV239 vaccine
was assessed according to anti-HEV IgG levels in the per-pro-
tocol cohort in months 0 and 7. Clinical hepatitis E cases were
detected through an active hepatitis E surveillance programme
and diagnosed as previously described [19]. Anti-HEV IgG level
was determined using a commercial ELISA (Beijing Wantai,
China). The assay was previously calibrated against a WHO
reference serum [20], which was assigned an antibody level of
100 WHO units (Wu)/mL. The assay cut-off recommended by
the manufacturer is equivalent to 0.077 Wu/mL and the
anti-HEV IgG level of test samples is expressed in Wu/mL.
Deﬁnitions of HEV infection and hepatitis E
Infection was indicated by a positive seroconversion, when
antibody level rose from negative to 0.154 Wu/mL, which is
twice the cut-off level, or by a four-fold or greater rise of
antibody level. Antibody level of the negative serum sample
was arbitrarily set as 0.0385 Wu/mL, which is half of the
cut-off level. A diagnosis of ‘hepatitis E case’ was deﬁned as
indicated when patients presented with hepatitis-like symp-
toms for ≥3 days, had peak serum alanine-leucine transaminase
concentration of ≥2.5 times the upper limit of normal and a
positive ﬁnding for at least two of the acute markers, anti-HEV
IgM, and at least a four-fold rise in IgG anti-HEV and/or RNA
[19].
Statistical analysis
Vaccine efﬁcacy and the 95% CI were calculated on the basis of
the observed difference between the vaccine group and the
placebo group. An exact conditional procedure was used to
evaluate vaccine efﬁcacy on the assumption that the number of
HEV infections in the vaccine and placebo groups are
independent Poisson random variables. All comparisons used
the two-sided Fisher exact test. Data analysis was performed
using SAS software (version 9.1; SAS Institute, Cary, NC,
USA). All reported p values are two-sided with a = 0.05.
Results
Analytical cohorts
Fig. 1 shows the analytical cohorts of the study. In total,
14 094 subjects were randomly assigned to the Hecolin
group or placebo group. Among them, 14 069 were tested for
anti-HEV before the ﬁrst injection and were competent for the
extended analysis (intention-to-treat cohort). The per-proto-
col (PP) cohort comprised 12 409 participants who received
three doses, and included 6176 participants in the Hecolin
group and 6233 participants in the placebo group. Among the
PP set, 8670 subjects provided paired serum samples in
months 7 and 19, 7478 subjects had paired samples taken in
month 19 and 31. The mean age, gender ratio, baseline
anti-HEV IgG seroprevalence and level were comparable
between the vaccine and placebo groups (Table 1).
The baseline anti-HEV IgG seroprevalence of the PP cohort
increased with age (Fig. 2a). The rate of increase was higher
for men than women before age 35 years and similar for either
gender at the later ages. Geometric mean concentration
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(GMC) of the antibody among the seropositive subjects was
stable among different age groups and between genders
(Fig. 2b). The anti-HEV IgG seroprevalence (Fig. 2c) and levels
of the placebo subjects (Fig. 2d) remained relatively constant
for the 31 months of the study.
Anti-HEV IgG response to vaccination
Vaccination induced a vigorous anti-HEV IgG response by
baseline seronegative subjects in the PP cohort, resulting in an
almost complete positive IgG anti-HEV seroconversion
(99.86%) with GMC rising to 15.08  0.47 Wu/mL. It was
further shown that pre-existing immunity boosted GMC of the
seropositive subjects to a signiﬁcantly higher level
(24.80  0.54 Wu/mL, p <0.0001). In the control group,
2.59% of the initially seropositive subjects underwent negative
seroconversion over the 7-month period due to natural
antibody decay and 3.16% of the initially seronegative subjects
underwent positive seroconversion, presumably in response
to HEV infection (Table 2). The seroprevalence of vaccinated
subjects (Fig. 2c) remained at >99% for at least 25 months
(Fig. 2c), as GMC declined from 19.13 (95% CI 18.74–19.53) at
1 month post-vaccination to 1.62 Wu/mL (95% CI 1.56–1.68)
at 25 months post-vaccination (Fig. 2d).
HEV serological events post-vaccination in the PP cohort
Antibody levels of most subjects in both groups declined
during the 12-monthly intervals (Fig. 3a,b). In the placebo
group, 115 subjects were infected by HEV, 98 of these
episodes were probably primary infections, indicated by
positive seroconversion, and 17 others were re-infection,
shown among seropositive subjects by a four-fold or greater
rise of antibody levels (Fig. 3a, dotted line); 145 others
underwent negative seroconversion during the same periods.
In the vaccine group, 24 subjects were infected and 80
others underwent negative seroconversion (Fig. 3b). Eighteen
of the episodes were breakthrough infections identiﬁed by a
four-fold or greater rise of antibody level, evidently having
evaded vaccine-induced immunity. The other six episodes
TABLE 1. Baseline characteristics of participants
Vaccine group Placebo group
Randomized participantsa 7048 7046
Men 2901 (41.16%) 2948 (41.84%)
Mean age (years) 44.4 (11.3) 44.4 (11.3)
Per-protocol populationb
(three doses)
6176 6233
Men 2457 (39.78%) 2524 (40.49%)
Mean age (years) 44.8 (11.1) 44.7 (11.1)
Age group (years)
16–20 207 (3.35%) 202 (3.24%)
21–30 472 (7.64%) 505 (8.10%)
31–40 1429 (23.14%) 1399 (22.45%)
41–50 1905 (30.85%) 1969 (31.59%)
51–60 1774 (28.72%) 1779 (28.54%)
61–65 389 (6.30%) 379 (6.08%)
Baseline anti-HEV
prevalence
47.57 (45.87–49.32) 46.48 (44.80–48.20)
GMC (Wu/mL)c 0.54 (0.52–0.57) 0.53 (0.51–0.56)
Data are number (%), mean (SD), or mean (95% CI).
GMC, geometric mean concentration; HEV, hepatitis E virus; Wu, WHO unit.
aAll randomized participants who received at least one dose of vaccine or placebo.
bPer-protocol population denotes all randomized participants who received three
doses of vaccine or placebo, and donated their serum samples on 0 months for
anti-HEV detection.
cOnly seropositive participants were calculated for GMC.
14 663 screened 
7048  
Hecolin® group 
11 were not tested for 
anti-HEV on 0m 
7037 were tested for anti-HEV on 0m 
   Anti-HEV (+): 3341; 3621 observed 
person-years;
   Anti-HEV (–): 3696; 4989 observed 
person-years 
14 094 
Randomization 
14 were not tested for 
anti-HEV on 0m 
7032 were tested for anti-HEV on 0m 
Anti-HEV (+): 3272; 3508 observed 
person-years; 
   Anti-HEV (–): 3760; 5056 observed 
person-years; 
7046  
Placebo group 
6176 receive 3 doses 
Anti-HEV (+): 2938 
3382 observed person-years: 
1802 were surveyed between 
months 7 to 18; 
1580 were surveyed between 
months 19 to 31 
 Anti-HEV (–): 3238 
4698 observed person-years: 
2520 were surveyed between 
months 7 to 18; 
2178 were surveyed between 
months 19 to 31 
243received 1 dose 
618 received 2 doses 
383 received dose 1,2 
235 received dose 1,3 
220 received 1 dose 
579 received 2 doses 
342 received dose 1,2 
237 received dose 1,3 
Intention-to-treat 
cohort: 14 069 
Per-protocol 
cohort: 12 409 
6233 receive 3 doses 
Anti-HEV (+): 2897 
3305 observed person-years: 
1772 were surveyed between 
months 7 to 18; 
1533 were surveyed between 
months 19 to 31 
 Anti-HEV (–): 3336 
4763 observed person-years: 
2576 were surveyed between 
months 7 to 18; 
2187 were surveyed between 
months 19 to 31 
FIG. 1. Analytical cohorts.
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were identiﬁed by positive seroconversion. Two of the latter
individuals did not show a detectable response to vaccination
and four others had since undergone negative seroconversion.
These six episodes were also considered to be breakthrough
infections for the purpose of analysis because the pre-infection
immune status of these individuals could not be ascertained.
The serological events described here did not show a
signiﬁcant gender (Fig. 3c) or age (Fig. 3d) difference, except
for primary infection in the placebo group, which exhibited a
signiﬁcant male bias compared with seronegative subjects as a
whole, and negative seroconversion among vaccinated subjects,
which was signiﬁcantly higher among elderly people. Three
episodes of primary infection among the control subjects
(arrows, Fig. 3a) were independently identiﬁed as conﬁrmed
hepatitis E cases through the hepatitis surveillance programme.
All the remaining 136 episodes were asymptomatic infections,
showing no or a minimum of symptoms and were not detected
in the concurrent hepatitis surveillance programme.
Anti-HEV IgG response to infection in the PP cohort
Fig. 4 shows the pre- and post-infection anti-HEV IgG levels of
98 individuals affected by primary infection (lanes B and C) and
17 individuals affected by re-infection (lanes E and F) in the
control group, and 24 individuals in the vaccine group affected
by breakthrough infection (lanes I and J), and the baseline
antibody levels of seropositive placebo subjects (lane A) and
vaccinated subjects (lane H). As a reference, antibody
responses to the episodes of asymptomatic infection were
compared with the antibody responses to 91 cases of sporadic
hepatitis E detected consecutively in a hepatitis E surveillance
study conducted in the same community in the preceding year
[21]; 82 of these cases were attributed to primary infection
(lane D) and nine to re-infection (lane G).
Antibody response to each kind of the infection varied
over a wide range between individuals, presumably partly
because of variations in doses of the infecting virus, immune
status of the individuals and individuality of antibody
response. The response to the asymptomatic episodes of
primary infection (lane C, GMC = 2.06  6.30 Wu/mL) was
signiﬁcantly lower than the response to disease attributed to
primary infection (lane D, GMC = 80.91  2.97 Wu/mL,
p <0.0001).
The pre-infection antibody levels of those in the control
group affected by re-infection (lane E, GMC = 0.40  1.65
Wu/mL) and those in the vaccine group affected by break-
through infection (lane I, GMC = 0.61  8.99 Wu/mL) were
not signiﬁcantly different (p 0.3518) and both were signiﬁcantly
lower than the corresponding baseline antibody levels of the
(a)
(c) (d)
(b)
FIG. 2. The anti-hepatitis E virus (HEV)
IgG status of cohorts. (a) Pre-vaccination
anti-HEV IgG prevalence among different
age groups. (b) Geometric mean
concentration (GMC) of seropositive
subjects in the per-protocol cohort. (c)
Anti-HEV IgG prevalence of vaccine and
placebo groups and (d) the GMC, among
the seropositive subjects of the respective
groups, before and at different months
after the ﬁrst dose.
TABLE 2. Anti-hepatitis E virus (HEV) IgG response to
HEV239 vaccine
Anti-HEV
IgG
Vaccine groupa Placebo groupa
Seropositive Seronegative Seropositive Seronegative
No. of
subjects
2659 2908 2626 2972
Positive rate (%)
0 months 100.00 0.00 100.00 0.00
7 months 99.96 99.86 97.41 3.16
GMCb (95% CI) (Wu/mL)
0 months 0.54
(0.51–0.56)
<0.077 0.53
(0.50–0.55)
<0.077
7 months 24.80
(24.26–25.36)
15.08
(14.61–15.56)
0.56
(0.54–0.59)
1.03
(0.65–1.63)
aResponse to vaccination was assessed in the per protocol set.
bThe geometric mean concentration (GMC) of the antibody was calculated among
the seropositive subjects.
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respective cohorts as a whole (lane A,
GMC = 0.61  3.32 Wu/mL, p <0.01; lane H, GMC =
7.76  3.90 Wu/mL, p <0.0001). Compared with the corre-
sponding pre-infection levels, antibody levels of the re-infected
subjects in the placebo group rose by 4.1- to 88.2-fold (mean
16.1-fold) to GMC of 3.68  2.30 Wu/mL (lane F) and the
antibody levels of the breakthrough infected subjects in the
vaccine group rose by 4.3- to 129.1-fold (mean 20.4-fold) to
GMC of 7.51  8.28 Wu/mL (lane J). The GMC level of the
response to asymptomatic episodes of re-infection (lane F) was
not signiﬁcantly different from that of breakthrough infection
(lane J, p >0.05).
Protection against HEV infection
Compared with seronegative placebo subjects, naturally
acquired immunity (RR = 0.25, 95% CI 0.15–0.42) and vac-
(a)
(c) (d)
(b)
FIG. 3. Anti-hepatitis E virus (HEV) IgG serological events after vaccination. (a) and (b) compare the IgG antibody levels of the ﬁrst (x-axis) and the
second (y-axis) of the paired serum samples obtained from subjects in the placebo (a) and vaccine (b) groups of the per-protocol infection subset in
months 7 and 19 or in months 19 and 31. Arrows indicate three conﬁrmed hepatitis E cases. Percent of men (c) and mean age (d) of those affected by
the different serological events identiﬁed in (a) and (b) (solid blocks) were compared with the corresponding values of the respective cohorts as a
whole (open blocks).
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O397–O405
CMI Zhang et al. Protection against hepatitis E virus infection O401
cine-induced immunity (RR = 0.15, 95% CI 0.09–0.22) signif-
icantly reduced risk of infection (Table 3). The risk of
re-infection observed in the placebo group, which had evaded
naturally acquired immunity (0.52%, 95% CI 0.30–0.83), was
similar to the risk of breakthrough infection observed in the
vaccine group, which had evaded vaccine-induced immunity
(0.30%, 95% CI 0.19–0.44), although GMC of the vaccine group
was substantially higher. Likewise, the risk of breakthrough
infection in the ﬁrst year (0.26%, 95% CI 0.12–0.44) and the
second year (0.35%, 95% CI 0.18–0.59) after vaccination was
similar, although baseline GMC levels had signiﬁcantly declined
in the interim.
Vaccine efﬁcacy against HEV infection was determined by
comparing the infection rates observed at different times
post-vaccination (Table 4). A full course of vaccination
achieved an overall efﬁcacy of 79.2% (95% CI 67.7–86.6) over
a 24-month period post-vaccination. The level of protection in
the ﬁrst year post-vaccination was similar to that in the second
year. The overall efﬁcacy calculated in participants who
FIG. 4. Anti-hepatitis E virus (HEV) IgG pre- and post-HEV infection. The line within the plots indicates the geometric mean concentration (GMC)
of anti-HEV. The GMC value and the sample size of each column are listed above the x-axis. Pre-inf, the latest sample collected before the infection;
Asympt-, after asymptomatic infection; Sympt-, after symptomatic infection; Post-inf, the ﬁrst sample collected after the infection.
TABLE 3. Protection against hepatitis E virus (HEV) infection by naturally acquired and vaccine-induced immunity
Group p-yr
Baseline GMC
(SD) (Wu/mL)
Infection
RREpisodes Rate (epi/100 p-yr)
Placebo 8068 — 115 1.43 (1.18–1.71) —
Seronegative 4797 <0.077 98a 2.04 (1.66–2.49) 1
Seropositive 3271 0.61 (3.32) 17 0.52 (0.30–0.83) 0.25 (0.15–0.42)
Hecolin 8080 7.76 (3.90) 24b 0.30 (0.19–0.44) 0.15 (0.09–0.22)
7–19 months 4322 18.18 (2.27) 11 0.26 (0.12–0.44) 0.12 (0.06–0.23)
19–31 months 3758 2.92 (3.28) 13 0.35 (0.18–0.59) 0.17 (0.09–0.29)
p-yr, person years.
aThree symptomatic hepatitis E cases concurrently detected through hepatitis surveillance system.
bThe pre-infection antibody levels of 18 individuals were <0.077 WHO units (Wu)/mL and those of the other six infected subjects were >0.077 Wu/mL (see Fig. 3).
TABLE 4. Efﬁcacy of HEV239 vaccine against hepatitis E
virus (HEV) infection
Cohorts
Months
post-
vaccination
Infection rate (episode/p-yr)
Efﬁcacy
(%, 95% CI)Vaccine Placebo
Per
protocol
1–24 0.30 (24/8080) 1.43 (115/8068) 79.2 (67.7–86.6)
1–12 0.26 (11/4322) 1.49 (65/4348) 83 (67.8–91.0)
13–24 0.35 (13/3758) 1.34 (50/3720) 74.3 (52.6–86)
Intention-
to-treat
1–24 0.33 (28/8610) 1.41 (121/8564) 77 (65.3–84.7)
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received at least one dose of vaccine (intention-to-treat set) is
77% (95% CI 65.3–84.7).
To evaluate the effect of antibody level on the protection
against infection, subjects were subgrouped based on their
anti-HEV level in month 7, at the beginning of the surveillance
(Table 5). The cumulative infection rate in seronegative subjects
of the placebo group was used as reference. Even the lowest
antibody level (0.077–0.25 Wu/mL) signiﬁcantly lowered the
risk to 0.26 (95% CI 0.11–0.65). Although the dose–effect is not
obvious, subjects with anti-HEV level >1.0 Wu/mL are signiﬁ-
cantly more protected than those with marginal antibodies.
Discussion
Previous studies identiﬁed the zoonotic genotype 4 virus to be
the dominant genotype prevalent in eastern and southern
China and pigs to be the principal reservoir for this virus, and
suggested that the virus is disseminated to the environment
through discharge of pig waste into the waterways [22,23].
Consistent with the latter ﬁnding, results of present study
found that infection is common and occurs at all age, with a
slight male preponderance. Among all the 115 infection
episodes, only three were clinical, the incidence of HEV
subclinical infection was 50 times higher than the incidence of
symptomatic hepatitis E disease and the antibody response to
the asymptomatic episodes of primary infection was substan-
tially lower than the response to disease attributed to primary
infection. In line with animal models [24], which showed that
the dose of the virus required to produce disease is about
1000 times higher than the infective dose, these ﬁndings
suggest that although widely distributed, the environmental
viral load of the study site is relatively low. The modest
antibody response to low level exposure to the virus balanced
by negative seroconversion due to natural immune decay had
resulted in a seroprevalence of 47% and a relatively low GMC
among the seropositive subjects of 0.5 Wu/mL and had served
to maintain the serological status of the cohort for the entire
31-month period of study and probably beyond. It is likely that
low-level exposure to zoonotic genotype 3 virus could
similarly account for the high seroprevalence and rare disease
reported for developed countries [25]. In contrast, an attack
rate of about 20–30% in subclinically infected subjects in Nepal
was reported [26], presumably due partly to the higher
environmental viral burden in areas where the virus is
hyperendemic.
Compared with seronegative subjects, natural immunity
had signiﬁcantly lowered infection risk, but does not entirely
prevent infection (Table 3). In overt cases, previous studies
also suggested that pre-existing immunity may limit the extent
of infection in individual patients, thereby alleviating severity of
illness and moderating antibody response [21]. Immunity
acquired from vaccination afforded a level of protection
similar to natural immunity. The rate of breakthrough
infection among vaccinated subjects was not signiﬁcantly
different from the rate of re-infection among seropositive
control subjects. The main beneﬁt of vaccination seems to be
that it confers protection on the entire population, whereas
natural immunity leaves more than half of the population
without the beneﬁts of immune protection. Vaccination
complements natural immunity by conferring additional pro-
tection against HEV infection over and above that afforded by
natural immunity.
Escape infection that had evaded naturally acquired or
vaccine-induced immunity accounted for 15% (17/115) of the
episodes of infection observed in the placebo group and most
probably for all 24 of the episodes of breakthrough infection
observed in the vaccine group. The risk of escape infection was
not associated with age or gender of the affected subjects. The
role of host immune surveillance is not clear, however. On the
one hand, the pre-infection antibody levels of the affected
subjects varied widely. The risk of escape infection did not
differ signiﬁcantly between the placebo and vaccine groups, nor
between those in the vaccine group in the ﬁrst and second
year post-vaccination, although the baseline antibody levels of
the respective groups differ substantially. Even the marginal
antibody level (0.077–0.25 Wu/mL) signiﬁcantly lowered the
risk (Table 5). However, although the dose–effect is not
obvious, subjects with an anti-HEV level >1.0 Wu/mL are
signiﬁcantly better protected than those with marginal anti-
bodies (Table 5). In addition, pre-infection antibody levels of
the affected subjects in the placebo and vaccine groups were
signiﬁcantly lower than the baseline antibody levels of the
TABLE 5. Relative risk of 2-year cumulative infection rate in
subjects with different level of baseline (7 months) anti-hep-
atitis E virus (HEV)
Anti-HEV level in
serum collected in
month 7 (Wu/mL) n
Cumulative
infection
episodes
Cumulative
rate (%)
Relative risk
(95% CI)
Undetectable
(in placebo group)
3011 93 3.1 —
0.077–0.25 614 5 0.8 0.26 (0.11–0.65)
0.25–0.5 746 15 2.0 0.65 (0.38–1.12)*
0.5–1.0 501 4 0.8 0.26 (0.09–0.70)
1.0–2.5 576 2 0.3 0.11 (0.03–0.46)
2.5–5 297 2 0.7 0.22 (0.05–0.88)
5.0–10 770 2 0.3 0.08 (0.02–0.34)
10–20.0 1575 3 0.2 0.06 (0.02–0.19)
≥20 3070 8 0.3 0.08 (0.04–0.17)
Subtotal
0.077–1.0 1861 24 1.3 0.58 (0.27–0.65)
≥1.0 6288 17 0.3 0.09 (0.04–0.17)
*The relative risk is not signiﬁcantly different from the reference seronegative
group.
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respective group of subjects as a whole. This discrepancy
remains to be investigated, but it would seem that, in general,
escape infection is relatively independent of the immune status,
age and gender of the host and it is possible that escape
infection is due in part to an intrinsic capacity of HEV to evade
host immune surveillance. Hence, the determination of the
antibody level that is protective against infection is not
possible. In contrast, the disease attributed to re-infection
was associated with a signiﬁcantly younger age and a larger
female preponderance (unpublished results), suggesting that
additional host factors might be involved in determining clinical
outcome of the infection.
The ﬁnding that the vaccine protects against infection has
expanded its potential application. In hyperendemic areas
where human genotype 1 or 2 is prevalent, vaccination could
lower environmental viral load, thereby further reducing the
risk of sporadic hepatitis E, recurrent outbreaks and out-
breaks in displacement camps. In other areas, including the
developed world, where the zoonotic genotypes 3 or 4 are
prevalent, vaccination may be considered for use with a view
to reducing serious complications associated with the infec-
tion in certain people, such as organ recipients [3], and those
with chronic liver diseases [16] or chronic virus infection [4].
Vaccination could also be considered for use to reduce
potential infection hazards posed by infected individuals, such
as food handlers and blood donors [27], to the community at
large.
Three virology markers were used to deﬁne HEV infection,
including positive anti-HEV IgM, positive HEV RNA and rising
anti-HEV IgG in paired serum samples [19]. As shown by
Huang et al. [21], the anti-HEV IgM antibody persisted for
about 16 weeks and the HEV RNA in serum persisted for
about 4 weeks after symptom onset, the time might be
shorter for asymptomatic HEV infection, so neither of these
two acute markers is appropriate in the present study when
sampling was performed at 12-monthly intervals. Anti-HEV IgG
induced by HEV infection might persist for years [25], which
made it the most reliable marker for identifying HEV
asymptomatic infection. The participants in this study had
their blood taken at 12-month intervals; some subjects might
have had increased IgG after HEV infection early in this period,
and then the IgG decayed to a pre-infection level by the end of
the interval, which might lead to detection being missed. This is
a limitation of this study, but taking blood at shorter intervals
was impractical for such a large cohort.
In conclusion, both vaccine-induced and naturally acquired
immunity can effectively protect against HEV infection.
Although partial population can beneﬁt from natural immunity,
the majority of the population would rely on vaccination to
gain protection against HEV infection.
Funding
Funding was received from the National High-tech R&D
Program (863 Programme) (2012AA02A408); National Major
Scientiﬁc and Technological Special Project for ‘Prevention and
Control of important infectious diseases’ (2012ZX10002001,
2011ZX10004-903) and National Major Scientiﬁc and Tech-
nological Special Project for ‘Signiﬁcant New Drugs Develop-
ment’ (2013ZX09101017); Fujian Provincial Science Fund for
Distinguished Young Scholars (2011J06015); Jiangsu Science
and Technology Support plan (BE2013723); and Grants from
Xiamen Innovax Biotech Company, Ltd.
Transparency Declaration
None to declare.
References
1. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging
infection in developed countries. Lancet Infect Dis 2008; 8: 698–709.
2. Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old
disease. J Hepatol 2008; 48: 494–503.
3. Kamar N, Selves J, Mansuy JM et al. Hepatitis E virus and chronic
hepatitis in organ-transplant recipients. N Engl J Med 2008; 358: 811–
817.
4. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage
of hepatitis E virus in patients with HIV infection. N Engl J Med 2009;
361: 1025–1027.
5. Teshale EH, Howard CM, Grytdal SP et al. Hepatitis E epidemic,
Uganda. Emerg Infect Dis 2010; 16: 126–129.
6. Guthmann JP, Klovstad H, Boccia D et al. A large outbreak of hepatitis
E among a displaced population in Darfur, Sudan, 2004: the role of
water treatment methods. Clin Infect Dis 2006; 42: 1685–1691.
7. Zhuang H, Cao XY, Liu CB, Wang GM. Epidemiology of hepatitis E in
China. Gastroenterol Jpn 1991; 26(Suppl 3): 135–138.
8. Dalton HR, Fellows HJ, Gane EJ et al. Hepatitis E in New Zealand. J
Gastroenterol Hepatol 2007; 22: 1236–1240.
9. Ijaz S, Arnold E, Banks M et al. Non-travel-associated hepatitis E in
England and Wales: demographic, clinical, and molecular epidemiolog-
ical characteristics. J Infect Dis 2005; 192: 1166–1172.
10. Mansuy JM, Abravanel F, Miedouge M et al. Acute hepatitis E in
south-west France over a 5-year period. J Clin Virol 2009; 44: 74–77.
11. Goel A, Aggarwal R. Hepatitis E: another effective vaccine, but will it
make a difference? Natl Med J India 2011; 24: 30–32.
12. Patra S, Kumar A, Trivedi SS, Puri M, Sarin SK. Maternal and fetal
outcomes in pregnant women with acute hepatitis E virus infection. Ann
Intern Med 2007; 147: 28–33.
13. Khuroo MS, Kamili S, Khuroo MS. Clinical course and duration of
viremia in vertically transmitted hepatitis E virus (HEV) infection in
babies born to HEV-infected mothers. J Viral Hepat 2009; 16: 519–
523.
14. Boccia D, Guthmann JP, Klovstad H et al. High mortality associated
with an outbreak of hepatitis E among displaced persons in Darfur,
Sudan. Clin Infect Dis 2006; 42: 1679–1684.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O397–O405
O404 Clinical Microbiology and Infection, Volume 20 Number 6, June 2014 CMI
15. Kumar Acharya S, Kumar Sharma P, Singh R et al. Hepatitis E virus
(HEV) infection in patients with cirrhosis is associated with rapid
decompensation and death. J Hepatol 2007; 46: 387–394.
16. Dalton HR, Hazeldine S, Banks M, Ijaz S, Bendall R. Locally acquired
hepatitis E in chronic liver disease. Lancet 2007; 369: 1260.
17. Zhang S, Wang J, Yuan Q et al. Clinical characteristics and risk factors
of sporadic Hepatitis E in central China. Virol J 2011; 8: 152.
18. Shrestha MP, Scott RM, Joshi DM et al. Safety and efﬁcacy of a
recombinant hepatitis E vaccine. N Engl J Med 2007; 356: 895–903.
19. Zhu FC, Zhang J, Zhang XF et al. Efﬁcacy and safety of a recombinant
hepatitis E vaccine in healthy adults: a large-scale, randomised,
double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895–
902.
20. Zhou C, Huang WJ, Yao X et al. Evaluation of the diagnostic kits for
hepatitis E and establishment of a quantiﬁcation method for detecting
anti-HEV IgG. Chin J Microbiol Immunol 2009; 29: 4.
21. Huang S, Zhang X, Jiang H et al. Proﬁle of acute infectious markers in
sporadic hepatitis E. PLoS One 2010; 5: e13560.
22. Li RC, Ge SX, Li YP et al. Seroprevalence of hepatitis E virus infection,
rural southern People’s Republic of China. Emerg Infect Dis 2006; 12:
1682–1688.
23. Zheng Y, Ge S, Zhang J et al. Swine as a principal reservoir of hepatitis
E virus that infects humans in eastern China. J Infect Dis 2006; 193:
1643–1649.
24. Li SW, Zhang J, Li YM et al. A bacterially expressed particulate hepatitis
E vaccine: antigenicity, immunogenicity and protectivity on primates.
Vaccine 2005; 23: 2893–2901.
25. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med 2012;
367: 1237–1244.
26. Clayson ET, Shrestha MP, Vaughn DW et al. Rates of hepatitis E virus
infection and disease among adolescents and adults in Kathmandu,
Nepal. J Infect Dis 1997; 176: 763–766.
27. Matsubayashi K, Kang JH, Sakata H et al. A case of transfusion-trans-
mitted hepatitis E caused by blood from a donor infected with hepatitis
E virus via zoonotic food-borne route. Transfusion 2008; 48: 1368–
1375.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O397–O405
CMI Zhang et al. Protection against hepatitis E virus infection O405
